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1. Introduction 
The cerebellum plays an important role in coordinated movement, motor learning and 
vestibular function. Cerebellar damage results in impaired body balance and disturbance in 
gait and posture. The cerebellum is impaired by various genetic diseases, such as 
spinocerebellar ataxia and mucopolysaccharidosis, and these diseases could be good  
candidates for gene therapy. There are at least two challenges that should be overcome 
before the clinical application of gene therapy is used to treat cerebellar disorders. The first 
challenge results from its large size, as the cerebellum is the second largest component of the 
central nervous system. The cerebellum can be subdivided into three main parts: the 
cerebrocerebellum, the vestibulocerebellum and the spinocerebellum (see Section 2 for 
details). Each subdivision in the cerebellum plays a distinct role and, to attain a satisfactory 
rescue of the cerebellar function by gene therapy, a therapeutic gene should be delivered 
efficiently and extensively into the large cerebellum.  
The second challenge is to deliver a gene into specific target cell populations in the 
cerebellum. In Parkinson's disease, which is caused by degeneration of nigra-striatal 
dopaminergic neurons, cell type-specific delivery of a therapeutic gene is a secondary 
matter, as the supply of sufficient amounts of dopamine, irrespective of neurons or glia, in 
the striatum is most critical for the functional recovery of the basal ganglia. By contrast, 
specific cell populations within the cerebellum, such as cerebellar Purkinje cells, Bergman 
glia or neurons in the deep cerebellar nuclei, are selectively impaired in most cerebellar 
diseases, such as spinocerebellar ataxia. Thus, affected cell types differ depending on the 
disease type, and the selective delivery of a therapeutic gene to a subset of affected cell types 
could be a key advance for rescuing cells that are degenerating from progressive damage, 
restoring cerebellar function and, ultimately, helping patients to recover from cerebellar 
ataxia.  
To this end, we have developed methods that allow for Purkinje cell-specific and Bergmann 
glia-specific gene expression in mice by modifying the culture conditions of lentiviral 
vector-producing human embryonic kidney (HEK) 293FT cells in combination with cell-
type-specific promoters in lentiviral vectors. Moreover, a new injection technique for 
efficient and widespread gene delivery into the cerebellar cortex has been devised, which 
takes advantage of the anatomical location of the cerebellum. Using the newly developed 
gene transfer method for the cerebellum, we aimed to restore the abnormal phenotypes of 
two types of ataxic mice, both of which are affected in Purkinje cells by different 
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pathologies. The results showed that the efficient and widespread delivery of therapeutic 
genes into Purkinje cells significantly restored ataxia and morphological and functional 
abnormalities of these cells in mutant mice. In this chapter, we describe our method that 
efficiently permits the selective gene delivery to cerebellar Purkinje cells or Bergmann glia 
and the rescue of two examples of ataxic mice. We also describe existing problems that 
should be resolved for the future clinical application of lentiviral vectors to cerebellar 
disorders.  
2. Cerebellar organization and neural circuits in the cerebellum 
The cerebellum can be subdivided into three main parts based on differences in their 
sources of input. The largest subdivision in humans is the cerebrocerebellum, which 
occupies most of the lateral hemisphere and is involved in the regulation of highly skilled 
movements, including speech. The vestibulocerebellum is the phylogenetically oldest part of 
the cerebellum; it comprises the caudal lobes of the cerebellum, including the flocculus and 
the nodulus, and is primarily engaged in the regulation of movements underlying posture 
and equilibrium. The last of the major subdivisions is the spinocerebellum, which occupies 
the median and paramedian zone of the cerebellar hemispheres. The spinocerebellum is the 
only part that receives input directly from the spinal cord. The lateral part and central part 
(vermis) of the spinocerebellum are involved in the movements of distal and proximal 
muscles, respectively. The vermis also regulates eye movements in response to vestibular 
inputs.  
The cerebellar cortex contains 5 neurons, the granule cell, the Purkinje cell and three 
inhibitory interneurons (stellate cell, basket cell and Golgi cell) and is divided into three 
morphologically distinct parts: the granule cell layer, the Purkinje cell layer, and the 
molecular layer (Fig. 1a and b). The granule cell layer contains numerous granule cells, in 
which Golgi cells are scattered. The Purkinje cell layer is a monolayer that consists of the 
soma of Purkinje cells and Bergmann glia; the Purkinje cells extend their well-differentiated 
dendrites into the molecular layer (Fig. 1c), where stellate cells and basket cells are located. 
The Bergmann glia also extend their processes into the molecular layer (Fig. 1b).   
A major input to the cerebellar cortex are the mossy fibers, axon bundles projecting from 
neurons in the thalamus, the brain stem and the spinal cord (Fig. 1b). The excitation of 
granule cells triggered by mossy fibers is transferred through the axons called parallel fiber 
to Purkinje cells. One Purkinje cell has more than one hundred thousand dendritic spines 
(Fig. 1d, arrows), on which parallel fiber terminals make excitatory synapses. Parallel fiber - 
Purkinje cell synapses are tightly wrapped by processes of Bergmann glia, so as to quickly 
take up the glutamate released from parallel fiber terminals. In this context, the Bergmann 
glia prevent the prolonged excitation of Purkinje cells and the spillover of glutamate that 
would activate the adjacent synapses.  
Another excitatory input to the cerebellar cortex is the climbing fiber that originates from 
neurons in the inferior olivary nucleus of the medulla oblongata. The climbing fiber makes 
excitatory synapses directly on proximal dendrites of Purkinje cells and neurons in the deep 
cerebellar nuclei. Excitatory activity of granule cells and Purkinje cells is modulated by 3 
types of inhibitory interneurons: Golgi cells, stellate cells, and basket cells. The Purkinje cells 
eventually integrate the information entered into the cerebellar cortex and send an 
inhibitory signal as the sole source of output from the cerebellar cortex to neurons in the 
deep cerebellar nuclei. 
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Fig. 1. Projections to and neural circuits in the cerebellar cortex. (a) A sagittal section of the 
vermis of a mouse cerebellum. (b) A schematic diagram of the cerebellar cortex that enlarges 
the square region in (a). ML, molecular layer; PCL, Purkinje cell layer; GCL, granule cell 
layer. A Purkinje cell (PC) receives excitatory inputs via parallel fibers (PF) and climbing 
fibers (CF) and sends inhibitory signals to neurons of the deep cerebellar nuclei (DCN). GC, 
granule cell, MF, Mossy fiber. (c) Well-differentiated dendrites of Purkinje cells are 
visualized by GFP expression. (d) Dendritic spines of Purkinje cells (arrows).  
3. Disorders of the cerebellum 
As cerebellar defects can be easily detected from overt ataxia, such as widespread gait and 
motor coordination deficits, numerous types of mutant mice with cerebellar degeneration 
have been isolated over the past 50 years. These mutant mice have contributed significantly 
to the elucidation of cerebellar physiology. At present, in parallel with advances in the 
development of viral vectors, we may be able to restore cerebellar defects of ataxic mice by a 
potential therapeutic gene delivery. Such rescue experiments have significant implications 
in terms of the future clinical application of gene therapy for patients suffering from 
cerebellar diseases. The following subsections summarize the cerebellar abnormalities and 
genetic defects identified in ataxic mice and humans.   
3.1 Spontaneously occurring ataxic mice 
Table 1 summarizes well-known murine mutants that cause cerebellar impairment. 
Recently, the genes responsible for those mutants have been identified and include missense 
mutations, nonsense mutations or frameshift mutations in the causative genes. The hotfoot 
mice are spontaneously occurring recessive mutants (Guastavino et al., 1990) that carry 
mutations in Grid2, which encodes the 2 glutamate receptor (GluR2) (Wang et al., 2003). 
To date, more than 10 mutant alleles have been identified; among these, hotfoot5J mice have 
been shown to carry a point mutation in exon 12 of Grid2, which creates a stop codon in the 
region encoding transmembrane 3 of GluR2 protein (Wang et al., 2003). The aberrant 
GluR2 protein is easily degraded and is not detected in Purkinje cells of hotfoot5J mice; 
therefore, hotfoot5J mice are mutants lacking GluR2 function.  
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Table 1. Genetic abnormalities and affected cell types in spontaneously occurring ataxic 
mice.  
Other loss-of-function mutants are Staggerer and Purkinje cell degeneration (pcd) mice. The 
staggerer mutation causes a functional impairment in a transcription factor, retinoid-related 
orphan receptor α (RORα), which belongs to the nuclear receptor superfamily (Boukhtouche 
et al., 2006; Gold et al., 2007). Staggerer mice have a 122-base pair deletion within the ligand 
binding domain (LBD) of the RORα gene (Hamilton et al., 1996). For PCD mice, 8 
independent alleles have been identified, which carry genetic mutations in the Nna1 gene, 
encoding a putative nuclear protein (Fernandez-Gonzalez et al., 2002; Wang & Morgan, 
2007). Most of the pcd alleles represent complete loss-of-function mutations. Because it is 
reasonable to postulate that aberrant phenotypes in loss-of-function mutants may be 
restored by introducing the intact gene, and, as Purkinje cells are the main cell type 
impaired in the loss-of-function mutants discussed here (hotfoot, staggerer and pcd), the 
efficient delivery of the intact gene into the specific subset of cells (Purkinje) may be a 
promising therapy for the recovery of those mutant mice from cerebellar degeneration and, 
ultimately, ataxia.  
There are two important points that should be addressed. First, gene delivery should be 
performed before Purkinje cells are substantially lost or irreversibly damaged. Purkinje cells 
of pcd mice die gradually from approximately 18 days of age and are virtually lost by 4 
months of age. Similarly, the Purkinje cell number in staggerer mice begins to decrease in the 
first week after birth, and at least 75-90% of Purkinje cells are lost in adult mutants (Vogel et 
al., 2000). The degeneration of Purkinje cells causes secondary defects of granule cells and 
neurons in the inferior olivary nucleus. Therefore, later gene delivery results in less or no 
functional recovery in staggerer and pcd mutants.  
Another important point is that gene delivery should be carried out before the Purkinje cell 
loses its plasticity. The compensation of a missing gene during an inappropriate time may 
result in the insufficient restoration of Purkinje cell abnormalities. By the second to third 
postnatal week, Purkinje cells extend dendrites and make a hundred thousand synapses 
with different counterparts. A series of developmental processes requires the strictly 
regulated expression of numerous genes, suggesting that the exogenous delivery of an intact 
gene after termination of this period may have little therapeutic impact. This period, in 
which the brain displays a heightened sensitivity to exogenous stimuli (and still maintains 
capacity to respond to gene therapy), is referred to as the “critical period”. The critical 
period differs depending on the defects of the mutant animals; thus, a careful examination 
using animal models can provide clues to deduce the critical period for the human 
cerebellum. 
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The Lurcher (Lc) mouse is an autosomal semidominant mutant that displays the 
degeneration of virtually all of the cerebellar Purkinje cells (Vogel et al., 2007). In 
heterozygous mice (Lc/+), cerebellar Purkinje cells specifically start to degenerate in a cell-
autonomous manner by postnatal day 8 (P8), and most die during the second postnatal 
week.; other cell types are eventually affected by secondary mechanisms (Wetts & Herrup, 
1982). Lc/+ mice exhibit severe ataxia during the third postnatal week, when approximately 
90% of the Purkinje cells have disappeared. Lc is caused by an alanine to threonine mutation 
in the highly conserved third hydrophobic segment of GluR2 (Zuo et al., 1997). As this 
region works as the gate of a cation channel (Kohda et al., 2000), the mutation converts the 
receptor into a constitutively leaky cation channel. Thus, lurcher is a gain-of-function 
mutation, suggesting that a simple delivery of the wild-type GluRα2 would not have a 
significant therapeutic impact on Lc Purkinje cells. A suppression of the mutant protein 
expression via, for example, RNA interference would be a promising gene therapy against 
disorders caused by a toxic-gain-of-function mutation.  
3.2 Human cerebellar diseases potentially treatable with gene therapy 
3.2.1 Spinocerebellar ataxia 
The cerebellum is impaired by various diseases, including neurodegenerative and enzyme-
deficient disorders. Spinocerebellar ataxia (SCA) is one of the representative diseases that 
affect the cerebellum. Approximately one third of the SCA in patients is hereditary. So far, at 
least 29 types of SCA result from chromosomal loci of the causal genes (Carlson et al., 2009), 
in which the major lesion of SCA type 1 (SCA1), SCA2, SCA6, SCA14, SCA17 and SCA31 
affects Purkinje cells. Neurons in the deep cerebellar nuclei are impaired in SCA3, and 
cortical Bergmann glia are primarily degenerated in SCA7. The well-known cause of 
hereditary SCAs is the abnormal expansion of trinucleotide (CAG) repeats in the coding 
region of genes responsible for the diseases. This expansion produces mutant proteins 
having an abnormally expanded polyglutamine stretch, leading to the formation of nuclear 
aggregates with other proteins that are critical for cellular functions. This type of hereditary 
SCAs is called polyglutamine disease and includes SCA1, SCA2, SCA3, SCA6, SCA7 and 
SCA17. As these diseases are caused by the production of toxic polyglutamine proteins 
(polyQ), a potential therapeutic approach would be to reduce the mutant polyQ by, for 
example, RNA interference (Xia et al., 2004) or the facilitation of their degradation. The latter 
may include the enhancement of the ubiquitin-proteasome pathway (Al-Ramahi et al., 2006; 
Matsumoto et al., 2004; Torashima et al., 2008; Wang & Monteiro, 2007) and autophagy 
(Menzies et al., 2010; Menzies & Rubinsztein, 2010; Williams et al., 2006).  
Autosomal dominant SCA14, characterized by severe cerebellar atrophy and ataxia, is 
caused by a missense mutation of the PRKCG gene, which encodes the protein kinase C 
(PKC) Ǆ gene. ǄPKC-deficient mice show only mild ataxia and no gross morphological 
abnormalities in the cerebellum (Chen et al., 1995; Kano et al., 1995), suggesting that the 
gain-of-toxic function, rather than loss-of-function, of ǄPKC underlies the pathology of 
SCA14. Therefore, a decrease in the amount of mutant ǄPKC protein is thought to be an 
effective therapy for SCA14. Indeed, recent studies have shown the allele-specific inhibition 
of mutant gene expression (Alves et al., 2008; Hu et al., 2009), and such mutant allele-
targeted RNA interference may result in better therapeutic efficacy.  
3.2.2 Mucopolysaccharidosis 
Lysosomal storage diseases (LSDs) are inherited metabolic disorders characterized by the 
accumulation of undigested macromolecules in the lysosomes due to a significant decrease 
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or a complete absence in the activity of soluble lysosomal enzymes (Neufeld, 1991). As most 
lysosomal enzymes are ubiquitously expressed, a deficiency in a single enzyme affects 
peripheral organs, as well as various regions of the brain, including the cerebellum. There 
are approximately 50 forms of inherited LSDs in humans with incidences of 1 in 7,000 live 
births (Haskins, 2009). LSDs are usually grouped biochemically by the accumulated 
metabolite into 3 subgroups: mucopolysaccharidoses (MPS), sphingolipidoses, and 
mucolipidoses.  
The potential treatments for LSDs include bone marrow or cord blood transplantation, 
enzyme replacement and gene therapy. Among the LSDs, those due to soluble lysosomal 
enzyme deficiencies are generally considered good candidates for gene therapy. These 
include MPS I, MPS IIIB and Niemann-Pick AB diseases (Sands & Davidson, 2006). To 
overcome the blood-brain barrier (BBB), viral vectors should be applied intrathecally 
(Watson et al., 2006) or directly into the brain parenchyma (Dodge et al., 2005), except in 
neonates having an incomplete BBB (Hartung et al., 2004; Kobayashi et al., 2005). Recent 
studies using knockout mouse models of MPS I and Niemann-Pick type A disease have 
shown a significant rescue of the phenotypic manifestations of the diseases upon 
intravenous and intrathecal application of adeno-associated virus (AAV) or lentiviral 
vectors expressing a deficient enzyme (Dodge et al., 2005; Hartung et al., 2004; Kobayashi et 
al., 2005; Watson et al., 2006). In addition, the injection of AAV vectors expressing the 
deficient gene, acid sphingomyelinase, into the deep cerebellar nuclei alleviated storage 
accumulation and corrected behavior deficits in the mouse model of Niemann-Pick type A 
disease (Dodge et al., 2005). These results suggest that viral vector-based gene transfer is 
promising for clinical gene therapy of patients with LSDs.  
4. Viral vector-mediated gene delivery to the cerebellum 
Vectors derived from retrovirus, Sindbis virus, adenovirus, lentivirus and AAV are widely 
used for gene transfer to mammalian cells; the properties of these vectors are summarized in 
Table 2. Retroviral vectors can express a foreign gene only in proliferating cells because they 
cannot pass through the nuclear membrane of host cells: the viral genome that enters into 
the cytoplasm of an infected cell can access the host chromosome only when the nuclear 
membrane disappears during mitosis. Exploiting this unique feature of retroviral vectors, 
they have been used to label neural stem cells (Kageyama et al., 2003; Levison et al., 2003; 
Namba et al., 2007).  
 
 
Table 2. Properties of different viral vectors. 
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Vectors based on Sindbis virus, a member of the Togaviridae family in the alphavirus 
subfamily, can infect non-dividing cells, including neurons, and replication occurs entirely 
in the cytoplasm of the infected cell as an RNA molecule (Griffin, 1998). Therefore, a high 
level of gene expression starts quickly after infection. One drawback of the Sindbis virus 
vector is high toxicity, as infected cells deteriorate within a couple of days.  
Adenoviral vectors are widely used as gene transfer vectors. They can accommodate a large 
gene of ~30 kb and infect both neurons and glia, with a higher tropism for glia. Therefore, 
adenoviral vectors have been used to modify the function of Bergmann glia (Iino et al., 
2001). Adenoviral vectors can exert toxicity to infected cells by triggering immune 
responses, and gene expression generally lasts only for ~2 months (Terashima et al., 1997). 
The features of adenoviral vectors, including their high infectivity in glial cells and 
immunogenicity, in combination with the introduction of an apoptosis-triggering gene are 
often applied to the gene therapy of malignant glioma (Horowitz, 1999; Jiang et al., 2009; 
Parker et al., 2009; Shinoura & Hamada, 2003).  
Vectors derived from lentiviruses, a genus of slow viruses of the Retroviridae family, can 
replicate in non-dividing neurons with little toxicity to the infected cells (Escors & Breckpot). 
Moreover, stable gene expression lasts for more than several years. In the cerebellum, 
lentiviral vectors pseudotyped with vesicular stomatitis virus glycoprotein (VSVG) can 
infect various types of cortical cells that include Purkinje cells, stellate cells, basket cells, 
Golgi cells, Bergmann glia and astrocytes (Croci et al., 2006; Torashima et al., 2006a). The 
properties of lentiviral vectors are described in more detail in the next section  
(Subsection 4.1). 
AAV is a non-pathogenic, small (20 nm), icosahedral and non-enveloped virus that belongs 
to the genus Dependovirus of the Parvoviridae family. Similar to lentiviral vectors, it infects 
both dividing and non-dividing cells with very little toxicity and a minimal immune 
response in the infected cells. To date, a number of AAV serotypes and over one hundred 
AAV variants have been isolated from adenovirus stocks or from human and non-human 
primate tissues (Gao et al., 2005; Wu et al., 2006). For gene transfer to cerebellar cells, AAV 
serotype 1, serotype 2 and serotype 5 (AAV1, AAV2 and AAV5) vectors have been used for 
the successful transduction of Purkinje cells (Alisky et al., 2000; Hirai, 2008; Kaemmerer et 
al., 2000; Xia et al., 2004). Thus, lentiviral vectors and AAV vectors, which have the potential 
to transduce Purkinje cells with almost no substantial toxicity, are promising as gene 
therapy vectors for cerebellar disorders that affect Purkinje cells. Because of the lack of 
pathogenicity, AAV vectors are increasingly becoming the vectors of choice for a wide range 
of gene therapy approaches. One major limitation of AAV vectors is the insert capacity, 
which is less than 4.7 kb, whereas lentiviral vectors have a higher capacity, up to 8 kb, for 
transgene accommodation (Table 2) (Hirai, 2008).  
4.1 Factors that control the tropism of lentiviral vectors for cerebellar neurons and 
glia 
As the VSVG binds to the phospholipids that constitute cellular membranes, VSVG-
pseudotyped lentiviral vectors are thought to infect mammalian cells without cell-type 
preference. In the cerebellar cortex, lentiviral vectors have successfully transduced Purkinje 
cells, three types of interneurons, Bergmann glia and astrocytes, but not granule cells. The 
efficient transduction of Golgi cells and astrocytes present in the granule cell layer suggest 
that the injected viral solution is accessible to granule cells: however, no or few transduced 
granule cells, if any, were detected upon injection of lentiviral vectors to the adult 
cerebellum in vivo (Croci et al., 2006; Torashima et al., 2006a).  
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The observed lentiviral tropism for Purkinje cells is affected by the serum-lot quality and 
cultivation period of the HEK293FT cells used for lentiviral production (Torashima et al., 
2006b). A three-day culture that causes the degeneration and death of HEK293FT cells 
results in the production of glia-tropic lentiviral vectors. Although the mechanism 
underlying this phenomenon has not been clarified, increases in the protease activity in the 
culture medium seems to be involved because the addition of a protease inhibitor in 
medium reversed the shift of lentiviral tropism from Purkinje cells to Bergmann glia (our 
unpublished observation). These results suggest that VSVG is modulated by a protease 
released from dead HEK293FT cells, leading to the alteration of lentiviral tropism.  
The L7/PCP2 promoter is a Purkinje cell-specific promoter, and the Gfa2 promoter works as 
an astrocyte-specific promoter. Therefore, the combination of the cultivation period of 
HEK293 FT cells for lentiviral production and the accommodation of the L7 or Gfa2 
promoter into lentiviral vectors permits us to specifically transduce Purkinje cells or 
Bergmann glia, respectively. However, these cell-type specific promoters generally have 
weak promoter strength. Therefore, the modification of these promoters, by the addition of 
an enhancer sequence and/or a significant increase in the viral titer by ultracentrifugation, is 
needed to attain sufficient levels of transgene expression. 
4.2 A method that enables efficient and widespread gene delivery to the cerebellum 
The cerebellum is a second largest organ in the mammalian CNS. Neurodegenerative 
diseases and congenital enzyme deficiency usually affect the entire cerebellar cortex, 
ranging from the vermis to the hemisphere, lobule 1 to lobule 10.  
For effective gene therapy, a wide range of therapeutic gene delivery methods is 
indispensable. Figure 2a is a photo of our viral injection system for the rodent brain.  
The injection of viral solutions to the brain parenchyma mechanically damages the tissue 
around an injection site, and ~1 µl is usually the limit for mouse brain regions, such as the 
striatum and hippocampus. However, we found that when injected at a speed of 0.2 – 0.3 
µl/minute, it was possible to apply 10 µl of viral solution to the subarachnoidal space over 
lobule 6 of the cerebellar cortex (Fig. 2b) without substantial damage to the cortical tissue. 
Injected viral particles spread through subarachnoidal spaces and infect Purkinje cells via 
their well-differentiated dendrites, leading to markedly efficient transduction of the Purkinje 
cells (Fig. 3). We have also verified that this injection method is applicable to neonatal pups 
and mature mice (Fig. 2c) (Sawada et al., 2010; Torashima et al., 2006a; Torashima et al., 
2006b). 
5. Lentiviral vector-based rescue of mice with cerebellar ataxia 
5.1 Hotfoot5J mice 
Hotfoot mice are spontaneously occurring recessive mutants (Guastavino et al., 1990), and 
mice homozygous for the mutation showed severe ataxia with jerky tapping of the 
hindlimbs, which can be noted by two weeks after birth. The Hotfoot5J allele possesses a 
point mutation in exon 12 of the GluRǅ2 gene, which creates a stop codon in the region 
encoding transmembrane 3 (Wang et al., 2003). Aberrant GluRǅ2 protein is easily degraded 
and not detected in the Purkinje cells of hotfoot5J mice. Therefore, hotfoot5J mice are thought 
to exhibit a similar phenotype to that of GluRǅ2 knock-out mice (Kashiwabuchi et al., 1995). 
Accordingly, we determined whether the ataxia of hotfoot5J mice could be reliably rescued 
by lentiviral-vector-based expression of the recombinant wild-type GluRǅ2 gene (Iizuka et 
al., 2009).  
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Fig. 2. Injection of viral vectors into the mouse cerebellum. (a) A viral vector injection setup. 
Viral vectors are injected very slowly with a speed of 0.2-0.3 µl/minute using an 
ultramicropump. (b) A schematic of the sagittal view of a mouse cerebellum depicting a 
viral injection site. (c) A schematic showing the availability of this injection method from a 
neonatal pup to a mature mouse. 
 
 
Fig. 3. Highly efficient transduction of Purkinje cells. Lentiviral vectors expressing GFP was 
injected as shown in Fig. 2. (a and b) Stereoscopic images of GFP fluorescence (a) and the 
superimposition with the whole brain (b) 7 days after the viral injection. (c) A GFP 
fluorescent image of Purkinje cells in the sagittal section.   
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Lentiviral vectors expressing GluRǅ2 plus GFP or GFP alone were injected into lobule 6 of 
the hotfoot5J cerebella at P6, and the motor control ability was assessed at P30 by footprints 
and a rotarod test. The footprint pattern of mutant mice was markedly ameliorated by the 
expression of GluRǅ2 plus GFP (Fig. 4).  
 
 
Fig. 4. Footprints of wild-type and hotfoot5J mice at P30. Ink was placed on the hindpaws of 
a non-injected wild-type mouse, a non-injected hotfoot5J mouse and hotfoot5J mice treated 
with GluRǅ2 plus GFP (+ GluRǅ2 & GFP); their footprints are shown. N.I., non-injected. 
 
 
Fig. 5. Rescue of rotarod performance of hotfoot5J mice treated with GluRǅ2 plus GFP. (a and 
b) Mice were assessed by two different tasks, an accelerating rod that reached 40 rpm from 0 
rpm in 3 min (a) and a stably rotating rod with a speed of 10 rpm (b). The results of non-
injected wild-type mice, non-injected hotfoot5J mice and hotfoot5J mice injected with lentiviral 
vectors expressing GluRǅ2 plus GFP or GFP alone are presented. Asterisks indicate 
statistically significant differences compared with non-injected hotfoot5J mice: *p < 0.05, ***p 
< 0.001 (One-way ANOVA). 
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In the rotarod analysis, mice treated with GluRǅ2 plus GFP showed significantly better 
performance at both acceleration and fixed-rod-speed tasks than non-injected mutant mice 
(Fig. 5), whereas neither the footprint pattern (not presented) nor the rotarod performance 
(Fig. 5) of hotfoot5J mice was altered by the injection of lentiviral vectors expressing only 
GFP. However, the rescue of ataxia by GluRǅ2 expression was obviously incomplete; 
GluRǅ2-treated hotfoot5J mice showed far poorer rotarod performance, particularly in the 
accelerating rod task (Fig. 5a), than wild-type mice. This was due partly to the expression of 
recombinant GluRǅ2 in restricted lobules of hotfoot5J cerebellum.  
Following the immunohistochemical examination, the GluRǅ2 immunoreactivity was absent 
in the Purkinje cells from the non-injected hotfoot5J mice, whereas efficient GluRǅ2 
expression was detected in the dendritic spines of Purkinje cells from hotfoot5J mice treated 
with lentiviral vectors expressing GluRǅ2 plus GFP.  
 
 
Fig. 6. Rescue from the persistent multiple CF innervation of hotfoot5J Purkinje cells by 
GluRǅ2 expression. (a) Representative CF-EPSCs recorded from Purkinje cells clamped at 
−10 mV in non-injected wild-type, non-injected hotfoot5J, GluRǅ2/GFP-treated hotfoot5J, and 
GFP-expressing hotfoot5J mice are shown. Scale bar, 500 pA, 10 ms. (B) Frequency 
histograms of Purkinje cells in terms of the number of discrete CF-EPSC steps in Purkinje 
cells from non-injected wild-type (42 cells, 3 animals), non-injected hotfoot5J (48 cells, 4 
animals), GluRǅ2/GFP-treated hotfoot5J (35 cells, 3 animals), and GFP-expressing hotfoot5J 
(40 cells, 3 animals) mice. N.I., non-injected. 
Previous electrophysiological studies indicated that the multiple climbing fiber innervation 
of Purkinje cells continued even after maturation in the GluRǅ2 knockout mice. GluRǅ2-/- 
Purkinje cells were innervated persistently by multiple climbing fibers (Hashimoto et al., 
2001; Ichikawa et al., 2002; Kashiwabuchi et al., 1995), and we examined whether the 
multiple innervations of hotfoot5J Purkinje cells were restored by the expression of 
recombinant GluRǅ2 using a patch-clamp technique. Only 18% of the Purkinje cells in P31-
P35 wild-type mice, and more than 60% of the Purkinje cells from age-matched GluRǅ2-null 
mice, were innervated by multiple climbing fibers (Fig. 6). The failure of the developmental 
removal of surplus climbing fibers was completely rescued by the lentiviral vector-mediated 
expression of GluRǅ2 plus GFP. However, no significant rescue was observed in hotfoot5J 
www.intechopen.com
 
Gene Therapy Application 
 
412 
cerebella expressing GFP alone. These results suggest a therapeutic potential of lentiviral 
vector-based gene therapy for cerebellar disorders that result from a loss-of-function gene 
mutation. 
5.2 The SCA model mice 
Polyglutamine diseases, including several autosomal dominant types of SCA, are inherited 
neurodegenerative diseases caused by expanded polyQ accumulation in neurons (Koshy & 
Zoghbi, 1997). Recent studies have identified proteins that facilitate the degradation of 
polyQ aggregates through a ubiquitin-proteasome pathway in cultured cells. Previously, 
Yanagi and colleagues have identified a novel guanosine triphosphatase (GTPase), CRAG, 
as one of those proteins. Furthermore, these authors have shown that CRAG triggers the 
nuclear translocation of a CRAG-polyQ complex, leading to the degradation of polyQ in 
HeLa cells (Qin et al., 2006). Because the expression of CRAG decreases in the adult brain, it 
is plausible that a reduced level of CRAG could underlie the onset of polyglutamine 
diseases. Therefore, we examined the potential of CRAG expression for treating 
polyglutamine disease and tested our hypothesis by lentivirally introducing CRAG into the 
cerebellar neurons of mice overexpressing polyQ in the cerebellum. 
 
 
Fig. 7. Severe cerebellar atrophy in the PolyQ mouse at P21 and P80. (a) A schematic 
depicting the transgene that drives the mutant ataxin-3(Q69) under the control of the L7 
promoter; an HA-tag was fused at the N-terminus of the truncated ataxin-3. Wild-type (b d, 
and f) and SCA3 model (c, e, and g) mice were fixed at P21 (b and c) or P80 (d-g). (b-e) A 
dorsal view of the whole brain; cerebella are indicated by arrows. Cb; cerebrum, IC; inferior 
colliculus, SC; superior colliculus, Sp; spinal cord. (f and g) Klüver–Barrera staining of 
sagittal sections of the cerebellum from a P80 SCA3 model mouse (g) and a wild-type 
littermate (f). Scale bars, 500 µm. 
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For this project, we generated transgenic mice (SCA model mice) expressing an expanded 
polyQ in cerebellar Purkinje cells using a truncated form of human ataxin-3, the gene 
responsible for Machado-Joseph disease (SCA3) with 69 CAG triplet repeats (ataxin-3[Q69]) 
(Kawaguchi et al., 1994; Yoshizawa et al., 2000) (Fig. 7a). The transgene expression was 
driven by a Purkinje cell-specific L7 promoter (Hirai et al., 2005). The SCA model mice 
started to show ataxic gait at approximately P10, which became more obvious as they 
developed further.  
The cerebella of SCA model mice at P21 and P80 were substantially smaller than that of 
wild-type littermates (Fig. 7b-g). A low magnification of the sagittal sections of the SCA 
model mouse cerebellum showed that the overall structure of the cortex was not grossly 
affected (Fig. 7g). However, examination at a higher magnification revealed that the 
Purkinje cells were markedly disarranged, concomitant with a substantial impairment of 
dendritic differentiation (Fig. 8).  
 
 
Fig. 8. Drastic morphological alteration in Purkinje cells of the SCA3 model mouse. 
Cerebellar sections from a P21 SCA3 model mouse (a) and a wild-type littermate (b) 
immunolabeled for calbindin. Note the markedly decreased thickness of the molecular layer 
and disarrangement of the Purkinje cell soma in the SCA3 model mouse cerebellum. Scale 
bar, 50 µm. 
Immunostaining of the cerebellar sections for the hemagglutinin (HA)-tag at the N-terminus 
of polyQ revealed a weak and diffuse accumulation of polyQ mainly in the nucleus of 
Purkinje cells at P21. The polyQ was markedly increased and formed numerous inclusion 
bodies in or around the Purkinje cell bodies by P80. In addition to the immunoreactivity in 
the Purkinje cell layer, small inclusion bodies with strong immunoreactivity for 
polyglutamine and ubiquitin were detected in the axon terminals of the Purkinje cells in the 
deep cerebellar nuclei.  
Lentiviral vectors expressing CRAG GTPase were injected into the midline cerebellar 
lobules of P21-P25 mice. The effect of CRAG or GFP expression was assessed by a rotarod 
test, in which mice were challenged with an accelerating rod paradigm just before or 4 or 8 
weeks after the viral injection (Fig. 9a). The rotarod performance of the non-injected SCA3 
model mice and the model mice expressing GFP alone deteriorated slightly at 8 weeks. In 
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contrast, the performance of mice treated with CRAG was significantly improved at both 4 
and 8 weeks after the injection, as compared with the results of non-injected mice. To 
examine the effect of CRAG expression on motor learning, mice were evaluated again by a 
rotarod test with a different paradigm, in which the rod speed was fixed at 5 rpm, and the 
trial was repeated 6 times. Non-injected SCA3 model mice and those treated with GFP 
showed almost no improvement in the performance even at the 6th trial (Fig. 9b). In 
contrast, mice treated with CRAG learned quickly how to stay on the rod, indicating the 
rescue of motor learning ability.  
 
 
Fig. 9. Rescue of the ataxic phenotype in polyQ mice upon the lentivector-mediated 
expression of CRAG. (a and b) Results of the rotarod test. The rod was accelerated from 0 
rpm and reached the maximum speed (40 rpm) in 3 min, as depicted above the graph (a). 
Mice treated with wild-type CRAG, but not those treated with GFP, exhibited significant 
improvement (a) (n = number of individual mice in each cohort). In the stable rod speed 
paradigm (5 rpm) administered 8 weeks after the injection, mice treated with CRAG learned 
quickly how to walk on the rod and showed a drastically better performance, compared 
with the non-injected and GFP-expressing mice (b). *p<0.05, **p<0.01, ***p<0.001, compared 
with results of non-injected mice. 
We next examined the cerebellar sections from untreated mice or mice treated with the 
lentiviral vectors by immunohistochemistry. Whereas strong labeling with numerous polyQ 
inclusions was observed in the cerebellar slices from non-injected polyQ mice and those 
injected with virus expressing GFP, the overall labeling with an anti-HA antibody for polyQ 
was faint and diffusely distributed in the cytoplasm and nuclei of the Purkinje cells in 
CRAG-expressing slices (Fig. 10a-d). Notably, the arrangement and dendritic differentiation 
of the Purkinje cells was altered upon the expression of CRAG. Double immunolabeling for 
calbindin and Flag-tag fused with CRAG showed that only the CRAG-expressing Purkinje 
cells extended dendrites. Consistently, the molecular layer was significantly wider in the 
cerebella of polyQ mice treated with CRAG than in those of non-injected animals (p<0.01, 
Fig. 10e). These in vivo data substantiated previous cell-culture-based results and further 
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extended the usefulness of the targeted delivery of genes facilitating the ubiquitin-
proteasome pathway as a gene therapy against polyglutamine diseases and other 
neurodegenerative disorders. 
 
 
Fig. 10. Degradation of polyQ aggregates in Purkinje cells by lentiviral-vector-mediated 
expression of CRAG. (a-d) Cerebellar sections from mice receiving no injection (a and b) or 
treated with CRAG (c and d). Upper panels are fluorescent images of polyQ immunolabeled 
for HA (green), which were merged with those of Purkinje cells immunolabeled for 
calbindin (magenta, lower panels). ML; molecular layer, PL; Purkinje cell layer. (e) A graph 
of the thickness of the molecular layer. The thickness of the molecular layer in the 
cerebellum from SCA3 model mice (Tg) treated without (Non-injected) or with CRAG and 
their wild-type littermates (WT) was measured, and the data were plotted on the graph. The 
average ± SD is presented beside the each plot. Three animals in each experimental group 
and virus vectors obtained from at least two independent cultures were used for 
quantitative analysis. Asterisks indicate significant differences compared with results of 
non-injected mice, **p<0.01. 
6. Underlying problems for the clinical application of lentiviral vectors to 
cerebellar diseases 
6.1 The significantly larger size of human cerebellum compared with the mouse 
cerebellum 
Figure 11 is a comparison of the mouse cerebellum with that of the cynomolgus monkey. 
Although our injection method allowed us to deliver a transgene very efficiently to mouse 
cerebellar cells, the human cerebellum is much larger than that of the cynomolgus monkey. 
Therefore, it is a tremendous challenge to attain the efficient transduction of Purkinje cells in 
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the human cerebellum. To overcome this volume problem, we are exploring ways to 
increase the amount of the viral solution from 10 µl to 1,000 µl and the number of injection 
sites from one to, for example, three points. 
 
 
Fig. 11. Comparison of the mouse cerebellum (right) with that of the cynomolgus monkey 
(left).  
6.2 Side effects that might be caused by the use of lentiviral vectors 
6.2.1 Toxicity of lentiviral vector infection on Purkinje cells 
Infection with Borna disease virus, an RNA virus tropic for cerebellar neurons, has been 
shown to cause developmental, neuroanatomical and behavioral abnormalities (Rubin et al., 
1999). HIV infection has also been shown to cause a decreased expression of mRNA and 
protein of AMPA-type glutamate receptors in cerebellar Purkinje cells (Everall et al., 1995). 
Compared with adenoviral vectors that have immunogenicity, lentiviral vectors cause 
almost no immune responses to infected cells and are thought to exert little toxicity on host 
cells. However, it has not been fully clarified whether the infection of high-titer lentiviral 
vectors lacks an adverse influence on neurons in vivo. To clarify the influence of high-titer 
lentiviral vector infection and the subsequent expression of the transgene, we injected 
lentiviral vectors having a titer of 1.0 x 1010 transduction units (TUs) into the neonatal rat 
cerebellum. Neonates were used for examining lentiviral toxicity because the brain is 
extremely vulnerable to developmental damage following perinatal insult.  
Lentiviral vectors expressing GFP under the control of the murine stem cell virus (MSCV) 
promoter were injected into the cerebellar cortex of neonatal rat pups. Three weeks after 
treatment, the GFP-expressing Purkinje cells were compared with control Purkinje cells 
from phosphate-buffered, saline-injected mice. An analysis of the dendritic tree showed that 
the total dendrite length in the GFP-expressing Purkinje cells was almost 80% of that in the 
control Purkinje cells. Furthermore, an electrophysiological examination showed that the 
short-term synaptic plasticity at the parallel fiber–Purkinje cell synapses and climbing fiber–
Purkinje cell synapses was significantly altered in the GFP-expressing Purkinje cells. In 
contrast, the morphological and functional maldevelopment of infected Purkinje cells was 
attenuated substantially when lentiviral vectors with much weaker promoter activity were 
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used. These results suggest that the maldevelopment of the Purkinje cells was caused 
mainly by the subsequent expression of a high amount of GFP driven by the strong MSCV 
promoter and that the toxic influence of lentiviral vector infection itself was minimal.  
6.2.2 Insertional mutagenesis 
Upon infection of a retrovirus into a cell, the viral RNA is inserted into the cytoplasm, where 
the RNA is reverse-transcribed into DNA by reverse transcriptase, which is then inserted 
into the host genome by an integrase. The viral genome sequence integrated into the host 
chromosome is called a “provirus”. The provirus insertion may disrupt regions of the host 
genome that are critical for cellular functions, such as the control of the cell cycle or 
apoptosis; this process is called “insertional mutagenesis”. In fact, ex vivo gene therapy using 
a murine leukemia virus (MLV) vector caused leukemia in 3 of the 11 children that were 
being treated for X-linked SCID (Hacein-Bey-Abina et al., 2003). However, lentiviral vectors 
are considered to be less likely to disturb the regulation and expression of host genes 
because of a difference of integration sites between the MLV vectors and lentiviral vectors: 
MLV vectors integrate primarily in promoter regions and CpG islands, whereas lentiviral 
vectors integrate into transcriptionally active genes (Mitchell et al., 2004; Schroder et al., 
2002). Although it is not clear whether insertional mutagenesis can lead to the 
transformation of postmitotic neurons, lentiviral vectors do infect and cause insertional 
mutagenesis in glial cells with proliferative properties. Therefore, the risk of insertional 
mutagenesis should be considered when lentiviral vectors are used clinically to treat 
neurological diseases (Jakobsson & Lundberg, 2006). 
7. Conclusion 
The cerebellum develops significantly after birth (Goldowitz & Hamre, 1998), and, therefore, 
the expression of various genes is strictly regulated. Cerebellar granule cell precursors that 
proliferate vigorously in the external granule cell layer migrate along the processes of 
Bergmann glia to form the internal granule cell layer during the first postnatal two weeks in 
rodents. The migrating granule cells supply trophic factors, such as brain-derived 
neurotrophic factor (BDNF), which stimulates the Purkinje cells to form differentiated 
dendrites (Schwartz et al., 1997). During the migration process, parallel fibers, granule cell 
axons, (Granule cell axons are called “parallel fibers”) make synapses with extending 
dendrites of Purkinje cells. Synaptic clefts between the parallel fibers and dendritic spines of 
a Purkinje cell are wrapped by processes of Bergmann glia that reuptake released glutamate, 
thereby modulate the synaptic transmission. Thus, 5 neurons and Bergmann glia in the 
cerebellar cortex concertedly elaborate the functional cerebellar neuronal circuit. One 
attractive therapy against diseases that impair Purkinje cells is the transplantation of 
Purkinje cells or their precursors engineered from stem cells into the damaged cerebellum. 
However, unless other cells surrounding Purkinje cells, such as the granule cells and 
interneurons, have sufficient plasticity, the transplanted Purkinje cells are not properly 
integrated to form a functional network, resulting in little therapeutic impact.  
In contrast, gene therapy aims to salvage degenerating Purkinje cells by delivering a 
therapeutic gene. Accordingly, when Purkinje cells are not lost, this approach is theoretically 
more effective than stem cell-based cell replacement therapy for diseases that impair 
Purkinje cells; this is despite the fact that the surrounding cells have only limited plasticity. 
To attain sufficient therapeutic efficacy in gene therapy, the broad and efficient gene 
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delivery to cerebellar neuronal or glial cells is indispensable, and this has been a significant 
challenge for decades. However, the problem is being solved by recent marked progress in 
both lentiviral and AAV vectors. The further accumulation of knowledge, including 
therapeutic genes and the critical period corresponding to distinct cerebellar defects, along 
with the development of animal models, would facilitate the clinical application of viral 
vector-based gene therapy for patients with various cerebellar disorders. 
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